DENTSPLY SIRONA Inc. (NASDAQ:XRAY)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a note issued to investors on Thursday. They presently have a $66.00 price target on the medical instruments supplier’s stock, down from their prior price target of $70.00. Stifel Nicolaus’ price objective would indicate a potential upside of 19.28% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. Goldman Sachs Group, Inc. (The) cut DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $60.00 to $55.00 in a research note on Tuesday, May 23rd. Zacks Investment Research upgraded DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research note on Wednesday, April 19th. Cleveland Research upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 23rd. HC Wainwright started coverage on DENTSPLY SIRONA in a research note on Tuesday, July 11th. They set a “buy” rating and a $74.00 target price on the stock. Finally, BidaskClub upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Friday, June 30th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $66.75.

DENTSPLY SIRONA (XRAY) opened at 55.33 on Thursday. The firm has a 50 day moving average of $62.91 and a 200 day moving average of $62.30. DENTSPLY SIRONA has a 12-month low of $54.49 and a 12-month high of $65.68. The firm’s market capitalization is $12.69 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.65. The company had revenue of $992.70 million for the quarter, compared to analysts’ expectations of $1 billion. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.76 EPS. On average, analysts forecast that DENTSPLY SIRONA will post $2.73 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Stock Rating Reaffirmed by Stifel Nicolaus” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://theolympiareport.com/2017/08/12/dentsply-sirona-inc-nasdaqxray-stock-rating-reaffirmed-by-stifel-nicolaus.html.

A number of large investors have recently made changes to their positions in XRAY. Ontario Teachers Pension Plan Board raised its stake in shares of DENTSPLY SIRONA by 10.2% in the second quarter. Ontario Teachers Pension Plan Board now owns 108,488 shares of the medical instruments supplier’s stock valued at $7,034,000 after buying an additional 10,049 shares during the period. Evercore Wealth Management LLC raised its position in DENTSPLY SIRONA by 10.8% in the second quarter. Evercore Wealth Management LLC now owns 3,096 shares of the medical instruments supplier’s stock worth $201,000 after buying an additional 303 shares during the last quarter. Epoch Investment Partners Inc. raised its position in DENTSPLY SIRONA by 3.5% in the second quarter. Epoch Investment Partners Inc. now owns 3,686,004 shares of the medical instruments supplier’s stock worth $239,001,000 after buying an additional 123,668 shares during the last quarter. Dimensional Fund Advisors LP raised its position in DENTSPLY SIRONA by 12.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,137,716 shares of the medical instruments supplier’s stock worth $73,768,000 after buying an additional 123,195 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in DENTSPLY SIRONA by 43.4% in the second quarter. Parametric Portfolio Associates LLC now owns 669,288 shares of the medical instruments supplier’s stock worth $43,397,000 after buying an additional 202,419 shares during the last quarter. 95.17% of the stock is owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.